Molnupiravir is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine and exerts its antiviral action by introducing copying errors during viral RNA replication.[13][14]
Molnupiravir was originally developed to treat influenza at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory (DRIVE), but was reportedly abandoned for mutagenicity concerns.[15][16] It was then acquired by Miami-based company Ridgeback Biotherapeutics, which later partnered with Merck & Co. to develop the drug further.[17]
Based on positive results in placebo-controlled double-blind randomized clinical trials,[18][19] molnupiravir was approved for medical use in the United Kingdom in November 2021.[7][20][21][22] In December 2021, the US Food and Drug Administration (FDA) granted an emergency use authorization (EUA) to molnupiravir for use in certain populations where other treatments are not feasible.[10] The emergency use authorization was only narrowly approved (13-10) because of questions about efficacy and concerns that molnupiravir's mutagenic effects could create new variants that evade immunity and prolong the COVID‑19 pandemic.[23][24][25] In September 2023, molnupiravir's mutagenicity was confirmed in a study of global SARS CoV 2 isolates after 2022: genomic changes were more common, especially where molnupiravir had been used.[26]
Medical uses
In the UK, molnupiravir is indicated for treatment of mild to moderate COVID‑19 in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness.[7]
In the US molnupiravir is unapproved but is authorized under an EUA for emergency use for the treatment of adults with mild-to-moderate COVID‑19 who are at high risk for progression to severe COVID‑19, including hospitalization or death, and for whom alternative COVID‑19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.[9][10][12]
Contraindications
Use during pregnancy is not recommended.[4] There are no human data on use during pregnancy to assess the risk of adverse maternal or fetal outcomes.[4] Based on animal data, the drug may cause fetal harm.[4]
Adverse effects
Adverse reactions observed in the phase III MOVe-OUT study included diarrhea (2%), nausea (1%) and dizziness (1%), all of which were mild or moderate.[12]
In rats, bone and cartilage toxicity was observed after repeated dosing.[12]
Overdose
The effects of overdose are unknown, treatment consists of general supportive measures such as monitoring of clinical status.[12]
Drug interactions
Based on limited available data, there are no drug interactions.[12]
Mechanism of action
Molnupiravir inhibits viral reproduction by promoting widespread mutations in the replication of viral RNA by RNA-directed RNA polymerase.[27] It is metabolized into a ribonucleoside analog that resembles cytidine, β-D-N4-hydroxycytidine 5′-triphosphate (also called EIDD-1931 5′-triphosphate or NHC-TP).[28][29][30] During replication, the virus's enzyme incorporates NHC-TP into newly made RNA instead of using real cytidine.[30]
Molnupiravir can swap between two forms (tautomers), one of which mimics cytidine (C) and the other uridine (U).[31] NHC-TP is not recognized as an error by the virus's proofreading exonuclease enzymes, which can replace mutated nucleotides with corrected versions.[27] When the viral RNA polymerase attempts to copy RNA containing molnupiravir, it sometimes interprets it as C and sometimes as U. This causes more mutations in all downstream copies than the virus can survive, an effect called viral error catastrophe or lethal mutagenesis.[31]
The international nonproprietary name of the drug was inspired by that of Thor's hammer, Mjölnir. The idea is that the drug will strike down the virus like a mighty blow from the god of thunder.[30]
In March 2020, the research team pivoted to studying SARS-CoV-2, and successfully used molnupiravir to treat human cells infected with the novel coronavirus.[33][unreliable medical source?] A study found that it is orally active against SARS-CoV-2 in ferrets.[34]
DRIVE then licensed molnupiravir for human clinical studies to Miami-based company Ridgeback Biotherapeutics, which later partnered with Merck & Co. to develop the drug further.[33][17]
The primary data supporting the US Food and Drug Administration (FDA) emergency use authorization for molnupiravir are from MOVe-OUT, a randomized, double-blind, placebo-controlled clinical trial studying molnupiravir for the treatment of non-hospitalized participants with mild to moderate COVID‑19 at high risk for progression to severe COVID‑19 and/or hospitalization.[10][35] Participants were adults 18 and older with a pre-specified chronic medical condition or at increased risk of SARS-CoV-2 infection for other reasons who had not received a COVID‑19 vaccine.[10] The main outcome measured in the trial was the percentage of people who were hospitalized or died due to any cause during 29 days of follow-up.[10] Of the 709 people who received molnupiravir, 6.8% were hospitalized or died within this period compared to 9.7% of the 699 people who received a placebo.[10]
In November 2022, the British National Institute for Health and Care Excellence decided molnupiravir should not be routinely used to treat COVID‑19, as research showed it made no significant difference to hospitalization or death rates and was not cost effective.[36] The drug was added to its "not recommended" list in draft COVID‑19 treatment guidance for consultation.[37][36]
Society and culture
Economics
In September 2021, Merck signed a voluntary licensing agreement with the Medicines Patent Pool (MPP) that allows MPP to sublicense molnupiravir and supply the COVID‑19 oral medication to 105 low- and middle-income countries. The cost of the US government's initial purchase was about $712 per course of treatment; treatment with generics in developing countries can cost as little as $20.[38][39]
Sales of molnupiravir were $952 million in the fourth quarter of 2021.[40]
Legal status
In October 2021, Merck submitted an EUA application to the FDA, and in November 2021, the FDA's Antimicrobial Drugs Advisory Committee (AMDAC) at the Center for Drug Evaluation and Research met to discuss the application.[41][42] The committee narrowly voted, 13 for and 10 opposed, to recommend authorization for adults with mild to moderate illness who are at high risk of developing severe COVID‑19.[43] Concerns were expressed over the drug's low effectiveness in preventing death, which in the final trial was only 30%, as well as the increased mutation rate the drug causes, which could theoretically worsen the pandemic by driving the evolution of more dangerous variants.[43][16] In December 2021, the US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for molnupiravir for the treatment of mild-to-moderate COVID‑19 in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progression to severe COVID‑19, including hospitalization or death, and for whom alternative COVID‑19 treatment options authorized by the FDA are not accessible or clinically appropriate.[10]
In November 2021, molnupiravir was approved in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of established infections of COVID‑19.[7] The MHRA issued a conditional marketing authorization applicable in the UK, and an emergency use authorization for Northern Ireland.[7][20][47][48]
At a November 2021 AMDAC meeting, multiple advisors raised the concern that molnupiravir could accelerate the emergence of variants of concern.[57][58] Other scientists raised similar concerns both before and after the meeting.[59][25][60][24] These concerns were confirmed with the September 2023 publication of a study of 15 million global SARS-CoV-2 sequences: after molnupiravir had been introduced in 2022, genomic changes were more common, especially where it had been used.[26]
Research
Alternative patented routes to molnupiravir have been reviewed.[61]
COVID-19 clinical trial
In October 2021, preliminary results from a clinical trial (MOVe-OUT)[62][63][full citation needed] indicated that treatment with molnupiravir may reduce the risk of hospitalization and death from COVID‑19.[64][65] The final analysis reported a 30% reduction in hospitalizations and deaths.[18][66]
Since December 2021, the PANORAMIC trial has been testing molnupiravir's effectiveness.[67][68] Results showed that for higher risk, vaccinated adults molnupiravir does not reduce the chances of hospitalisation and death. However it results in faster recovery and reduced viral load.[69][70]
In February 2023, Merck reported that the phase III MOVe-AHEAD trial to evaluate the safety and efficacy of Lagevrio compared to placebo in preventing the spread of SARS-CoV-2 within households did not meet its primary endpoints. With more than 1,500 participants who were free of COVID‑19 and lived with someone who was recently diagnosed with the virus, patients treated with Lagevrio were 23.6% less likely than those on placebo to develop COVID after 14 days.[71][72][73]
^ abUS application 20200276219, Painter GR, Bluemling GR, Natchus MG, Guthrie D, "N4-hydroxycytidine and derivatives and anti-viral uses related thereto", published 2020-09-03, assigned to Emory UniversityArchived 5 October 2021 at the Wayback Machine
^World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85". WHO Drug Information. 35 (1). hdl:10665/340684.
^World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 87". WHO Drug Information. 36 (1). hdl:10665/352794.
^Wruhs O (1986). "[Comparative study of stability following the nailing of fractures of the femur shaft. An experimental study with cadaver bones]". Wiener Klinische Wochenschrift. Supplementum (in German). 169: 3–16. PMID3464133.
^Clinical trial number NCT04575597 for "Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)" at ClinicalTrials.gov
Zakaria Aboukhlal Aboukhlal bermain untuk Toulouse pada 2022Informasi pribadiNama lengkap Zakaria Aboukhlal[1]Tanggal lahir 18 Februari 2000 (umur 24)[1][2]Tempat lahir Rotterdam, Belanda[3]Tinggi 179 cm (5 ft 10 in)[2]Posisi bermain PenyerangInformasi klubKlub saat ini ToulouseNomor 6Karier junior Willem II PSV EindhovenKarier senior*Tahun Tim Tampil (Gol)2018–2019 Jong PSV 25 (9)2019 PSV 2 (0)2019–2022 Jong AZ 19 (13)2019–2022 A…
Coming Around Againsingolo discograficoCarly Simon nel video musicale di Coming Around AgainArtistaCarly Simon Pubblicazione1986 Durata3:31 Album di provenienzaComing Around Again Dischi1 Tracce2/3 GenerePopPop rock EtichettaArista Records ProduttoreBill PayneGeorge MassenburgPaul Samwell-SmithRuss Kunkel Registrazione1986 Formati45 giri, 45 giri maxi, CD singolo CertificazioniDischi d'argento Regno Unito[1](vendite: 200 000+) Carly Simon - cronologiaSingolo precedenteTire…
Questa voce sull'argomento contee del Kentucky è solo un abbozzo. Contribuisci a migliorarla secondo le convenzioni di Wikipedia. Contea di MasonconteaLocalizzazioneStato Stati Uniti Stato federato Kentucky AmministrazioneCapoluogoMaysville Data di istituzione1788 TerritorioCoordinatedel capoluogo38°36′00″N 83°49′48″W / 38.6°N 83.83°W38.6; -83.83 (Contea di Mason)Coordinate: 38°36′00″N 83°49′48″W / 38.6°N 83.83°W38.6; -83.…
Alpen KitzbühelHahnenkamm (1,712m/5,616ft) di atas KitzbühelTitik tertinggiPuncakKreuzjochKetinggian2.558 m (8.392 ft)Letak GeografisAustriaNegara BagianSalzburg and TirolRange coordinates47°15′6″N 11°58′57″E / 47.25167°N 11.98250°E / 47.25167; 11.98250 Alpen Kitzbühel (Jerman: Kitzbüheler Alpencode: de is deprecated atau Kitzbühler Alpen) adalah kawasan pegunungan yang merupakan bagian dari Pegunungan Alpen Timur Tengah. Pegunungan ini …
2014 Ulster SFCTournament detailsYear2014WinnersChampionsDonegal (8th win)ManagerJim McGuinnessCaptainMichael MurphyRunners-upRunners-upMonaghanManagerMalachy O'RourkeCaptainConor McManus← 20132015 → Championship venuesCeltic Park in the City of DerryHealy Park in OmaghSt Tiernach's Park in Clonesand others elsewhere... The 2014 Ulster Senior Football Championship was the 126th[1] installment of the annual Ulster Senior Football Championship held under the auspices …
Ruddi Setiawan Direktur Narkotika BNN Informasi pribadiLahir24 September 1974 (umur 49)Surabaya, Jawa TimurSuami/istriNy. Ni Wayan Sari UtariAnak1. SR2. KH3. ARAlma materAkademi Kepolisian (1996)Karier militerPihak IndonesiaDinas/cabang Badan Narkotika NasionalMasa dinas1996—sekarangPangkat Brigadir Jenderal PolisiSatuanReserseSunting kotak info • L • B Brigjen. Pol. Ruddi Setiawan, S.I.K., S.H., M.H. (lahir 24 September 1974) adalah seorang perwira tinggi Polri ya…
Kolonel Inf. Budi Yuono adalah seorang perwira menengah TNI AD yang saat ini bertugas sebagai Irut II/Minlat Itlatitum Itjenad. Budi Yuono merupakan alumni Akademi Militer 1995 yang mahir dalam kecabangan Infanteri dan terakhir bertugas sebagai Komandan Kodim 0832/Surabaya Selatan.Budi Yuono Irut II/Minlat Itlatitum ItjenadPetahanaMulai menjabat 28 Oktober 2021Komandan Kodim 0832/Surabaya SelatanMasa jabatan30 Juni 2020 – 28 Oktober 2021 PendahuluKolonel Inf. Moch Sjamsul AriefPen…
Potret Sir Eric Drummond Sir Eric Drummond adalah seorang negarawan berkebangsaan Inggris.[1] Dia lahir di Fulford, Yorkshire pada tanggal 17 Agustus tahun 1876 dan meninggal dunia saat 15 Desember 1951 di Rogate, Sussex.[1] Dia merupakan sekretaris jenderal pertama dalam Liga Bangsa-Bangsa, yakni mulai tahun 1919 sampai 1935.[1] Selanjutnya ketika 1925 sampai tahun 1930, Drummond mengadakan perjalanan muhibah (kunjungan persahabatan), tempat yang dituju antara lain adala…
Nama ini menggunakan cara penamaan Spanyol: nama keluarga pertama atau paternalnya adalah Delgado dan nama keluarga kedua atau maternalnya adalah Chalá. Agustín Delgado Informasi pribadiNama lengkap Agustín Javier Delgado ChaláTanggal lahir 23 Desember 1974 (umur 49)Tempat lahir Ambuquí, Imbabura, EcuadorTinggi 1,88 m (6 ft 2 in)Posisi bermain PenyerangKarier senior*Tahun Tim Tampil (Gol)1991–1993 ESPOLI 12 (6)1994–1995 Barcelona SC 11 (2)1995–1996 El Nacional…
Artikel ini sebatang kara, artinya tidak ada artikel lain yang memiliki pranala balik ke halaman ini.Bantulah menambah pranala ke artikel ini dari artikel yang berhubungan atau coba peralatan pencari pranala.Tag ini diberikan pada Oktober 2022. ElgatoJenis produkConsumer electronics (computer)PemilikCorsair Gaming, Inc.Diluncurkan2010; 14 tahun lalu (2010)Pemilik sebelumnyaElgato SystemsSitus webwww.elgato.com/en Elgato adalah merek produk teknologi konsumen. Merek ini diproduksi dan diranc…
Artikel ini perlu diterjemahkan dari bahasa Inggris ke bahasa Indonesia. Artikel ini ditulis atau diterjemahkan secara buruk dari Wikipedia bahasa Inggris. Jika halaman ini ditujukan untuk komunitas bahasa Inggris, halaman itu harus dikontribusikan ke Wikipedia bahasa Inggris. Lihat daftar bahasa Wikipedia. Artikel yang tidak diterjemahkan dapat dihapus secara cepat sesuai kriteria A2. Jika Anda ingin memeriksa artikel ini, Anda boleh menggunakan mesin penerjemah. Namun ingat, mohon tidak menyal…
Artikel ini sebatang kara, artinya tidak ada artikel lain yang memiliki pranala balik ke halaman ini.Bantulah menambah pranala ke artikel ini dari artikel yang berhubungan atau coba peralatan pencari pranala.Tag ini diberikan pada November 2022. Annie Birgit GardeLahir3 Oktober 1933 (umur 90)Frederikssund, DenmarkPekerjaanPemeranTahun aktif1955–kini Annie Birgit Garde (lahir 3 Oktober 1933) adalah seorang pemeran film Denmark. Ia tampil dalam 31 film sejak 1955.[1] Ia lahir d…
Ini adalah nama Korea; marganya adalah Joo. Brian JooInformasi latar belakangNama lahirBrian Gintaek JooNama lainBrian G. Joo, Brian Minkyu Joo, Joo Min-kyoo (주민규)Lahir10 Januari 1981 (umur 43)New Jersey, Amerika SerikatAsalAbsecon, New Jersey, Amerika SerikatGenre Pop K-pop R&B Soul Gospel CCM Pekerjaan Penyanyi Penulis lagu Komponis Produser rekaman Pemeran Pemandu acara televisi Instrumen Vokal Piano Keyboard Drum Tahun aktif1999–sekarangLabelHiCC MediaJellyfish Entertainment…
This biography of a living person needs additional citations for verification. Please help by adding reliable sources. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libelous.Find sources: List of International cricket families – news · newspapers · books · scholar · JSTOR (December 2010) (Learn how and when to remove this template mess…
Artikel ini sebatang kara, artinya tidak ada artikel lain yang memiliki pranala balik ke halaman ini.Bantulah menambah pranala ke artikel ini dari artikel yang berhubungan atau coba peralatan pencari pranala.Tag ini diberikan pada November 2022. Cleo MooreCleo pada tahun 1956LahirCleouna Moore(1929-10-31)31 Oktober 1929[1]Galvez, Louisiana, A.S.Meninggal25 Oktober 1973(1973-10-25) (umur 43)Inglewood, California, A.S.Tahun aktif1948–1957Suami/istriPalmer Long ̴…
The following is a list of current and historic aircraft of the South African Air Force. Current aircraft Further information: South African Air ForceThese aircraft are in service as of 2024[1] Aircraft Image Origin Type Variant Introduction In service Notes Combat Aircraft JAS 39 Gripen Sweden Multirole fighter C/D 2010 26[2] JAS 39C: 17 JAS 39D: 9 BAE Hawk United Kingdom / South Africa Fighter trainer Mk. 120 2006 24[3] Tanker KC-390 Millennium Brazil / South Africa Aer…
Halaman Universitas Al-Qarawiyyin di Fes, Maroko. Salah satu sudut Fakultas Ekonomi, Universitas Indonesia pada 2013. Di Indonesia, perguruan tinggi (disingkat PT atau Perti) adalah satuan pendidikan yang menyelenggarakan pendidikan tinggi dan dapat berbentuk akademi, politeknik, sekolah tinggi, institut, atau universitas. Perguruan tinggi berkewajiban menyelenggarakan pendidikan, penelitian, dan pengabdian kepada masyarakat. Perguruan tinggi dapat menyelenggarakan program akademik, profesi, dan…
IVE아이브IVE pada October 2023Dari kiri ke kanan: Rei, Gaeul, Wonyoung, Yujin, Leeseo, LizInformasi latar belakangAsalSeoul, Korea SelatanGenreK-popTahun aktif2021 (2021)–sekarangLabelStarship EntertainmentSitus webSitus web resmiAnggota Yujin Gaeul Rei Wonyoung Liz Leeseo IVE (Hangul: 아이브; Katakana: アイヴ) adalah grup idola wanita dari Korea Selatan yang dibentuk oleh Starship Entertainment pada tahun 2021. Grup ini ini terdiri dari enam anggota yaitu Gaeul, Yujin, …